经口部分喉切除术联合Zeitels喉镜及钬激光治疗42例声门型喉癌的疗效
Efficacy of transoral partial laryngectomy with zeitels and holmium laser in 42 glottic cancers.
文献信息
| PMID | 42749788 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Hongyu Wang |
| 作者单位 | Department of Otolaryngology, Head and Neck Surgery, School of Clinical Medicine, Tsinghua Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, 102200, China. |
| 期刊 | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery |
| SCI 分区 | Q1 |
| IF | 2.3 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 咽喉科 |
中文摘要
目的： 评估使用悬吊式Zeitels喉镜系统联合钬激光辅助（SZL-HoL）的经口部分喉切除术治疗声门型喉癌的疗效。
方法： 对2017年1月至2025年1月期间接受SZL-HoL的42例患者和接受开放性部分喉切除术（OPL）的43例患者进行回顾性分析。患者为T1b-T2期及部分选择性T3期声门型喉癌。研究比较了生存率、术中出血量、气管切开率及拔管时间、鼻胃管置入率及拔除时间、术后嗓音恢复情况以及住院时间。
结果： 与OPL组相比，SZL-HoL组患者显示出更优的五年总生存率（92.3% vs. 81.32%，P = 0.045），尽管两组之间的疾病特异性生存率和局部控制率未达到统计学显著性。SZL-HoL组在术中出血量、术后嗓音质量、气管切开持续时间、鼻胃管留置时间以及住院时间方面也表现出更好的结果。
结论： SZL-HoL是治疗T1b-T2期及部分选择性T3期声门型喉癌的一种有效且安全的手术方法，在适当选择的患者中可提供良好的功能结局和可接受的肿瘤学安全性。
英文摘要
OBJECTIVE: To evaluate the efficacy of transoral partial laryngectomy using the suspension Zeitels laryngoscope system and holmium laser assistance (SZL-HoL) in the treatment of glottic laryngeal cancer.
METHODS: A retrospective analysis was conducted on 42 patients who underwent SZL-HoL and 43 patients who underwent Open Partial Laryngectomy (OPL) from January 2017 to January 2025. Patients had T1b-T2 and selected T3 glottic cancer. The study compared survival rates, intraoperative blood loss, tracheotomy rates and decannulation times, nasogastric tube placement rates and removal times, postoperative voice recovery, and hospital stay.
RESULTS: Patients in the SZL-HoL group showed Table five-year overall survival compared with those in the OPL group (92.3% vs. 81.32%, P = 0.045), although disease-specific survival and local control did not reach statistical significance between the two groups. The SZL-HoL group also had better outcomes in terms of intraoperative blood loss, postoperative voice quality, duration of tracheotomy, duration of nasogastric tube placement, and length of hospital stay.
CONCLUSION: SZL-HoL is an effective and safe surgical approach for the treatment of T1b-T2 and selected T3 glottic cancer, offering favorable functional outcomes with acceptable oncological safety in appropriately selected patients.